Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.

David Z I Cherney,Ele Ferrannini,Guillermo E Umpierrez,Anne L Peters,Julio Rosenstock,David R Powell,Michael J Davies,Phillip Banks,Rajiv Agarwal

Diabetes, obesity & metabolism（2023）

引用 3|浏览22

暂无评分

摘要

After 26 weeks, HbA1c was significantly reduced with sotagliflozin 400 but not 200 mg compared with placebo in this CKD3 cohort. UACR in patients with at least A2 albuminuria was reduced with each of the two doses at 26 weeks, but changes were not sustained at week 52. The safety findings were consistent with previous reports (NCT03242252).

查看译文

关键词

SGLT inhibitors,antihyperglycaemic therapy,severe renal impairment,sotagliflozin,stage 3 chronic kidney disease,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要